Disparities in prostate cancer in African American men: What primary care physicians can do

Cleveland Clinic Journal of Medicine

Volumn 79, Issue 5, 2012, Pages 313-320

  Wu, Ina ^a   Modlin, Charles S ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; ARTICLE; EARLY DIAGNOSIS; ETHNOLOGY; GENERAL PRACTITIONER; GENETICS; HEALTH CARE DISPARITY; HUMAN; MALE; PROSTATE TUMOR; RISK REDUCTION;

AFRICAN AMERICANS; EARLY DETECTION OF CANCER; HEALTHCARE DISPARITIES; HUMANS; MALE; PHYSICIANS, PRIMARY CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK REDUCTION BEHAVIOR;

EID: 84862983847     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.79a.11001     Document Type: Article

References (78)

1. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD. http:// seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010. Accessed April 2, 2011.
2. Arias E. United States life tables, 2007. National vital statistics reports; vol 59 no 9. Hyattsville, MD: National Center for Health Statistics. 2011.
3. Klein JB, Nguyen CT, Saffore L, Modlin C 3rd, Modlin CS Jr. Racial disparities in urologic health care. J Natl Med Assoc 2010; 102:108- 117.
4. Wells TS, Bukowinski AT, Smith TC, et al. Racial differences in prostate cancer risk remain among US servicemen with equal access to care. Prostate 2010; 70:727-734.
5. Smedley BD, Stith AY, Nelson AR, editors. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Institute of Medicine. National Academy Press; 2002.
6. Odedina FT, Akinremi TO, Chinegwundoh F, et al. Prostate cancer disparities in black men of African descent: a comparative literature review of prostate cancer burden among black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer 2009; 4(suppl 1):S2.
7. Okobia MN, Zmuda JM, Ferrell RE, Patrick AL, Bunker CH. Chromosome 8q24 variants are associated with prostate cancer risk in a high risk population of African ancestry. Prostate 2011; 71:1054-1063.
8. Haiman CA, Chen GK, Blot WJ, et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet 2011; 7:e1001387.
9. Freedman ML, Haiman CA, Patterson N, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 2006; 103:14068-14073.
10. Chang BL, Isaacs SD, Wiley KE, et al. Genome-wide screen for prostate cancer susceptibility genes in men with clinically significant disease. Prostate 2005; 64:356-361.
11. Hatcher D, Daniels G, Osman I, Lee P. Molecular mechanisms involving prostate cancer racial disparity. Am J Transl Res 2009; 1:235-248.
12. Robbins CM, Hooker S, Kittles RA, Carpten JD. EphB2 SNPs and sporadic prostate cancer risk in African American men. PLoS One 2011; 6:e19494.
13. American Cancer Society. Cancer Facts & Figures for African Americans 2009-2010. http://www.cancer.org/acs/groups/content/@nho/ documents/document/cffaa20092010pdf.pdf. Accessed April 2, 2012.
14. Ayanian JZ, Udvarhelyi IS, Gatsonis CA, Pashos CL, Epstein AM. Racial differences in the use of revascularization procedures after coronary angiography. JAMA 1993; 269:2642-2646.
15. Fine MJ, Ibrahim SA, Thomas SB. The role of race and genetics in health disparities research. Am J Public Health 2005; 95:2125-2128.
16. Horner RD, Oddone EZ, Matchar DB. Theories explaining racial differences in the utilization of diagnostic and therapeutic procedures for cerebrovascular disease. Milbank Q 1995; 73:443-462.
17. Juckett G. Cross-cultural medicine. Am Fam Physician 2005; 72:2267- 2274.
18. Ndubuisi SC, Kofie VY, Andoh JY, Schwartz EM. Black-white differences in the stage at presentation of prostate cancer in the District of Columbia. Urology 1995; 46:71-77.
19. Misra-Hebert AD. Physician cultural competence: cross-cultural communication improves care. Cleve Clin J Med 2003; 70:289, 293, 296-298.
20. Powell I, Sakr W, Weiss L, et al. Prostate cancer is biologically more aggressive among African Americans than Caucasian men under age 70: hypothesis supported by autopsy and SEER data. Program and abstracts from the American Urological Association 95th Annual Meeting; April 29-May 4, 2000: Atlanta, GA.
21. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 2010; 183:1792-1796.
22. Kim HS, Moreira DM, Jayachandran J, et al. Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men. Prostate Cancer Prostatic Dis 2011; 14:262-265.
23. Duffy MJ. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening? Ann Clin Biochem 2011; 48:310-316.
24. Andriole GL, Crawford ED, Grubb RL 3rd, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310-1319.
25. Crawford ED, Grubb R 3rd, Black A, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2011; 29:355-361.
26. Schröder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320-1328.
27. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11:725-732.
28. Chornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 2011; 71:985-997.
29. Boyd MD, Weinrich SP, Weinrich M, Norton A. Obstacles to prostate cancer screening in African-American men. J Natl Black Nurses Assoc 2001; 12:1-5.
30. Freedland SJ, Isaacs WB. Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate 2005; 62:243-252.
31. Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2008; 17:636-644.
32. Hosain GM, Sanderson M, Du XL, Chan W, Strom SS. Racial/ethnic differences in predictors of PSA screening in a tri-ethnic population. Cent Eur J Public Health 2011; 19:30-34.
33. Carpenter WR, Howard DL, Taylor YJ, Ross LE, Wobker SE, Godley PA. Racial differences in PSA screening interval and stage at diagnosis. Cancer Causes Control 2010; 21:1071-1080.
34. Betancourt JR, Maina AW. The Institute of Medicine report " Unequal Treatment" : implications for academic health centers. Mt Sinai J Med 2004; 71:314-321.
35. Patel K, Kenerson D, Wang H, et al. Factors influencing prostate cancer screening in low-income African Americans in Tennessee. J Health Care Poor Underserved 2010; 21(suppl 1):114-126.
36. Modlin CS. Culture, race, and disparities in health care. Cleve Clin J Med 2003; 70:283-288.
37. Kyle C, Ewing T, Wu XC, et al. Statewide analysis of serum prostate specific antigen levels in Louisiana men without prostate cancer. J La State Med Soc 2004; 156:319-323.
38. Vijayakumar S, Winter K, Sause W, et al. Prostate-specific antigen levels are higher in African-American than in white patients in a multicenter registration study: results of RTOG 94-12. Int J Radiat Oncol Biol Phys 1998; 40:17-25.
39. Chang BL, Spangler E, Gallagher S, et al. Validation of genomewide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev 2011; 20:23-32.
40. National Comprehensive Cancer Network (NCCN). NCCN Stresses Importance of PSA Testing in High-Risk Men. http://www.nccn.org/ about/news/newsinfo.asp?NewsID=218. Accessed April 2, 2012.
41. National Cancer Institute. Prostate-Specific Antigen (PSA) Test. http://www.cancer.gov/cancertopics/factsheet/detection/PSA. Accessed April 2, 2012.
42. Duggan D, Zheng SL, Knowlton M, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. Natl Cancer Inst 2007; 99:1836-1844.
43. Grossfeld GD, Latini DM, Downs T, Lubeck DP, Mehta SS, Carroll PR. Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? J Urol 2002; 168:2510-2515.
44. Hoffman RM, Harlan LC, Klabunde CN, et al. Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study. J Gen Intern Med 2003; 18:845-853.
45. Polednak AP. Prostate cancer treatment in black and white men: the need to consider both stage at diagnosis and socioeconomic status. J Natl Med Assoc 1998; 90:101-104.
46. Merrill RM, Lyon JL. Explaining the difference in prostate cancer mortality rates between white and black men in the United States. Urology 2000; 55:730-735.
47. Tewari AK, Gold HT, Demers RY, et al. Effect of socioeconomic factors on long-term mortality in men with clinically localized prostate cancer. Urology 2009; 73:624-630.
48. White A, Coker AL, Du XL, Eggleston KS, Williams M. Racial/ethnic disparities in survival among men diagnosed with prostate cancer in Texas. Cancer 2011; 117:1080-1088.
49. Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol 2010; 28:1069- 1074.
50. Demers RY, Tiwari A, Wei J, Weiss LK, Severson RK, Montie J. Trends in the utilization of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality. Cancer 2001; 92:2309-2317.
51. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006; 11:1388-1413.
52. Schwartz K, Powell IJ, Underwood W 3rd, George J, Yee C, Banerjee M. Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer. Urology 2009; 74:1296-1302.
53. Hayn MH, Orom H, Shavers VL, et al. Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/ regional prostate cancer. Cancer 2011. [Epub ahead of print]
54. Du XL, Lin CC, Johnson NJ, Altekruse S. Effects of individual-level socioeconomic factors on racial disparities in cancer treatment and survival: findings from the National Longitudinal Mortality Study, 1979-2003. Cancer 2011; 117:3242-3251.
55. Winkfield KM, Chen MH, Dosoretz DE, et al. Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 20115; 81:e345-e350.
56. Fowler JE Jr, Terrell F. Survival in blacks and whites after treatment for localized prostate cancer. J Urol 1996; 156:133-136.
57. Tewari A, Horninger W, Badani KK, et al. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int 2005; 96:29-33.
58. Bozeman C, Williams BJ, Whatley T, Crow A, Eastham J. Clinical and biopsy specimen features in black and white men with clinically localized prostate cancer. South Med J 2000; 93:400-402.
59. Delongchamps NB, Singh A, Haas GP. Epidemiology of prostate cancer in Africa: another step in the understanding of the disease? Curr Probl Cancer 2007; 31:226-236.
60. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 2002; 90:162-173.
61. Muller DC, Severi G, Baglietto L, et al. Dietary patterns and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2009; 18:3126-3129.
62. Alexander DD, Mink PJ, Cushing CA, Sceurman B. A review and meta-analysis of prospective studies of red and processed meat intake and prostate cancer. Nutr J 2010; 9:50.
63. Gonzalez CA, Riboli E. Diet and cancer prevention: contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Eur J Cancer 2010; 46:2555-2562.
64. Rodriguez C, McCullough ML, Mondul AM, et al. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol Biomarkers Prev 2003; 12:597-603.
65. McCarty MF. Mortality from Western cancers rose dramatically among African-Americans during the 20th century: are dietary animal products to blame? Med Hypotheses 2001; 57:169-174.
66. Rodriguez C, Freedland SJ, Deka A, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2007; 16:63-69.
67. Spangler E, Zeigler-Johnson CM, Coomes M, Malkowicz SB, Wein A, Rebbeck TR. Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men. J Urol 2007; 178:1939-1944.
68. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301:39-51.
69. Oakley-Girvan I, Feldman D, Eccleshall TR, et al. Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Cancer Epidemiol Biomarkers Prev 2004; 13:1325- 1330.
70. Gilbert R, Martin RM, Beynon R, et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 2011; 22:319-340.
71. Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011; 128:1414-1424.
72. Yin L, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk. Cancer Epidemiol 2009; 33:435-445.
73. McCormick DL, Johnson WD, Bosland MC, Lubet RA, Steele VE. Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor. Nutr Cancer 2007; 57:184-193.
74. Belpomme D, Irigaray P, Ossondo M, Vacque D, Martin M. Prostate cancer as an environmental disease: an ecological study in the French Caribbean islands, Martinique and Guadeloupe. Int J Oncol 2009; 34:1037-1044.
75. Ramis R, Diggle P, Cambra K, López-Abente G. Prostate cancer and industrial pollution. Risk around putative focus in a multi-source scenario. Environ Int 2011; 37:577-585.
76. Dey S, Zhang Z, Hablas A, et al. Geographic patterns of cancer in the population-based registry of Egypt: possible links to environmental exposures. Cancer Epidemiol 2011; 35:254-264.
77. Watters JL, Park Y, Hollenbeck A, Schatzkin A, Albanes D. Cigarette smoking and prostate cancer in a prospective US cohort study. Cancer Epidemiol Biomarkers Prev 2009; 18:2427-2435.
78. Orsini N, Bellocco R, Bottai M, et al. A prospective study of lifetime physical activity and prostate cancer incidence and mortality. Br J Cancer 2009; 101:1932-1938.